Vall d’Hebron University Hospital and the biotechnology company Goodgut, a HIPRA group company, both CataloniaBio  & HealthTech members, are launching a study to implement RAID-Dx, a non-invasive diagnostic test for irritable bowel syndrome (IBS). The study will be conducted with 300 patients with symptoms of the disease.

RAID-Dx  is the first non-invasive diagnostic test to diagnose IBS by determining the specific microbial signature of this disease in stool. In addition, this tool developed by GoodGut helps discriminate this syndrome from other inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, which have similar symptoms.

The use of the RAID-Dx diagnostic test in primary care will reduce the time it takes for these patients to be diagnosed and to get optimal treatment, which should significantly improve their quality of life. In addition, using RAID-Dx is expected to eliminate at least 30% of current diagnostic procedures, as they only rule out other diseases, and will speed up the referral of these patients to specialized care, all in all, improving the efficiency of the use of health system resources.

In this study, individuals who were previously diagnosed with IBS and had symptoms at the time of inclusion in the study will be subjected to the RAID-Dx test to assess the clinical performance of the instrument. In addition, the impact on the patient's quality of life will be measured based on the improvement in the speed of diagnosis and access to treatment, as well as the savings it can represent.

Irritable Bowel Syndrome currently affects around 11% of the European population and is among the 10 most difficult diseases to detect, with a diagnosis lasting between 1 and 5 years.